The hydroxypropyl–β-cyclodextrin complexation of toltrazuril for enhancing bioavailability
Authors Zhang L, Liu MX, Lu CC, Ren DD, Fan GQ, Liu C, Liu MJ, Shu G, Peng GN, Yuan ZX, Zhong ZJ, Zhang W, Fu HL
Received 20 November 2017
Accepted for publication 14 December 2017
Published 19 March 2018 Volume 2018:12 Pages 583—589
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Qiongyu Guo
Li Zhang,1,2,* Mengxi Liu,1,* Chaocheng Lu,1 Dandan Ren,1 Guoqing Fan,1 Chang Liu,1 Mengjiao Liu,1 Gang Shu,1 Guangneng Peng,1 Zhixiang Yuan,1 Zhijun Zhong,1 Wei Zhang,1 Hualin Fu1
1Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China; 2Institute of Traditional Chinese Medicine Pharmacology and Toxicology, Sichuan Academy of Chinese Medicine Sciences, Chengdu, Sichuan, China
*These authors contributed equally to this work
Introduction: Toltrazuril (Tol) is used to prevent and combat coccidiosis. However, its low aqueous solubility and poor oral bioavailability limit clinical application.
Methods: To overcome the shortcomings, toltrazuril–hydroxypropyl–β-cyclodextrin inclusion complex (Tol-HP-β-CD) was prepared and characterized. The comparative plasma disposition kinetics of Tol was analyzed after a single orally administered dose of 10 mg/kg Tol or Tol-HP-β-CD in rabbits. Solution-stirring method was selected to prepare the inclusion complex. Complex formation was characterized by thin-layer chromatography, Fourier transform infrared spectrophotometry, and 1H nuclear magnetic resonance spectroscopy. In plasma profile, plasma samples were collected between 1 and 10 days following administration. Plasma Tol concentrations were determined by high-performance liquid chromatography.
Results: In rabbit plasma, the time to peak concentration (Tmax) of Tol-HP-β-CD was shorter than that of Tol (12 h vs 24 h). Cmax (19.92±1.02 µg/mL) and area under the concentration–time curve (AUC0-∞, 1,176.86±70.26 mg/L h) of the Tol-HP-β-CD group significantly increased (p<0.01) than those of the Tol group (Cmax, 8.02±1.04 µg/mL; AUC0-∞, 514.03±66.65 mg/L h).
Conclusion: It can be concluded that the Tol-HP-β-CD increased the aqueous solubility and enhanced the oral bioavailability in rabbits. Complexation with HP-β-CD is a feasible way to prepare a rapidly absorbed and more bioavailable Tol oral product.
Keywords: toltrazuril, coccidian, hydroxypropyl–β-cyclodextrin, inclusion complex, pharmacokinetics
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]